Aveanna (AVAH) Q4 2025 Earnings Call Transcript

Q4 revenue of $662M (+27.4% YoY) and adjusted EBITDA of $85M (+54% YoY); full-year 2025 revenue $2.433B (+20.2%) and adjusted EBITDA $320.8M (+74.8%), aided in part by an extra 53rd week. Liquidity at quarter-end was $529M (cash $193M, $110M securitization availability, $226M undrawn revolver), with $1.49B variable-rate debt ( $520M hedged via swaps through Jun-2026; $880M SOFR-capped at 3% through Feb-2027). 2026 guidance: revenue $2.54B–$2.56B and adjusted EBITDA $318M–$322M (excludes Family First acquisition), while Family First deal is ~$175.5M consideration (~$120M revenue, ~7.5x post-synergy EBITDA) targeted to close late Q2. Key risks: no material California PDN rate increase modeled for 2026–27 and Medical Solutions gross margin expected to normalize to ~43%–45% after a $2.5M–$3M reserve release boosted Q4 results.

Analysis

Aveanna’s playbook—densify preferred-payer penetration, lean into episodic contracts, and bolt on niche tuck‑ins—creates optionality that is underappreciated by simple revenue-growth models. Dense payer coverage in a region converts fixed acquisition and back‑office costs into higher incremental margin on new volumes, while also shortening the payor negotiation cycle for wage pass‑throughs; that creates a compounding return to scale that is asymmetrical versus small single‑state operators.

Two under‑the‑radar exposures matter for risk-adjusted sizing. First, the company’s hedging schedule and reliance on receivable-backed securitization concentrate refinancing and liquidity risk in a narrow 12–18 month window; a colder-than‑expected legislative season or a slowdown in claims collections could force higher funding costs or tighter securitization covenants. Second, temporary reserve releases and one‑off synergies mask the baseline earnings power of the Medical Solutions leg—if collections revert or margins normalize on timing, near‑term upside will compress faster than street estimates expect.

M&A is a lever, not a free option: tuck‑ins that increase regional density are value accretive faster than bolt‑on revenue buys, but purchase multiples are already elevated relative to mid‑cycle compaction scenarios. Finally, California’s political and reimbursement uncertainty makes it a strategic drag rather than systemic risk: the company can offset state setbacks by accelerating densification elsewhere, but competitors focused solely on the troubled state could suffer market-share losses or forced consolidation.

Time horizons: operational and payer wins crystallize over 6–12 months; liquidity and hedge expiry are near‑term catalysts over the next 9–15 months. Watch legislative calendars, securitization utilization, and quarter‑to‑quarter collections cadence as the highest‑information signals.

Key Decisions for Investors

• AVAH long (core): Accumulate on 10–15% pullbacks over the next 3 months, sizing to 2–4% portfolio. Rationale: payer density and predictable free‑cash conversion provide asymmetric upside; set a hard stop at 12% downside. Target 20–30% total return over 12 months if payer wins and deal integration track to plan.
• AVAH options (leveraged, defined risk): Buy 9–12 month call spreads (establish long-dated call spread roughly 10–25% out‑of‑the‑money) sized at 25–50% of the equity allocation to gain upside while capping premium outlay. R/R: limited downside (premium) vs ~2–4x upside if multiple and payer expansion re-rate.
• Event hedge around Q1/May budget: Buy short-dated (4–8 week) protective puts into the Q1 print and state budget season (size 25–30% of position) to protect against payroll‑tax seasonality and adverse legislative outcomes. This reduces tail downside while keeping upside exposure intact.
• Pair/relative value: Long AVAH / short a single-state or CA‑centric home‑care operator (small size) to isolate the preferred‑payer execution story and dodge regional reimbursement shock. Use this to neutralize macro rate moves and focus P&L on execution differential.